Commitment - We Will

At Janssen we are driven by dedication to patient care, medical innovation and customer focus. Our vision is to provide innovative solutions to those living with - and caring for - people with mental illness. Since our founding in 1953 by Dr Paul Janssen - a prominent researcher, pharmacologist and physician - and the discovery of HALDOL® (haloperidol) in 1958, Janssen has been firmly grounded in science and the search for innovation. Now, Janssen is focused exclusively on mental health. In partnership with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., we are dedicated to, organized for, and exploring and developing new treatments for mental illnesses. This focus enables us to build on our rich heritage and innovative therapeutic advances. We continue to be at the forefront of groundbreaking research, to develop the most effective treatments possible, and advocate every day for patients with mental illness, their caregivers and the treatment teams who work so hard to help them live their lives to the fullest. We've set out specific We Will Initiatives that simplify our focus and amplify our dedication. Find out what WE WILL is all about and read about the initiatives that express our commitment to mental health.